ClinConnect ClinConnect Logo
Search / Trial NCT06579547

Evaluating Replacement of Standard-of-care Low Dose Computer Tomography (CT) Scans With Radiation-free Bone Imaging by Deep-learning Augmented Zero Echo Time (DL-ZTE) Magnetic Resonance Tomography (MRT)

Launched by ROMAN GUGGENBERGER · Aug 27, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new way to look at bone structures in people with joint diseases and inflammation, using a technique called Deep Learning Enhanced Magnetic Resonance Imaging (MRI). Unlike traditional CT scans, which use X-rays and expose patients to radiation, this new MRI method aims to visualize bones without any radiation. The researchers want to find out if this new MRI can show bone details as clearly as a CT scan and if it can be used as a safer alternative in the future.

To participate in the trial, individuals aged 65 to 74 who have been referred for an MRI to check for joint issues may be eligible, provided they are willing to sign a consent form and do not have any conditions that would prevent them from having a CT scan. Participants will receive both an MRI and a CT scan of the same area to help researchers compare the two methods. This study is currently looking for volunteers, and it’s a great opportunity to contribute to safer imaging techniques in medicine.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Referral for a clinically indicated MRI examination of the musculoskeletal system to assess inflammatory and degenerative joint changes.
  • Willingness to sign the informed consent form.
  • No contraindications for a CT examination (e.g., claustrophobia).
  • Exclusion Criteria:
  • No signed informed consent form.
  • Patients under 18 years of age.
  • Pregnant women.
  • The calculated effective dose of the CT examination exceeds 5 mSv.

About Roman Guggenberger

Roman Guggenberger is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a strong background in clinical development and a focus on innovative therapeutic solutions, he leads initiatives that prioritize rigorous scientific methodology and compliance with regulatory standards. His collaborative approach fosters partnerships with healthcare professionals and research institutions, ensuring the successful execution of trials that address unmet medical needs. Guggenberger's dedication to ethical practices and patient welfare underscores his reputation as a trusted leader in the clinical research community.

Locations

Zürich, , Switzerland

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported